These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27536110)

  • 1. Clinical characteristics of synthetic cannabinoid-induced psychosis in relation to schizophrenia: a single-center cross-sectional analysis of concurrently hospitalized patients.
    Altintas M; Inanc L; Oruc GA; Arpacioglu S; Gulec H
    Neuropsychiatr Dis Treat; 2016; 12():1893-900. PubMed ID: 27536110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics of synthetic cannabinoid-induced psychotic disorders: a single-center analysis of hospitalized patients.
    Skryabin VY; Vinnikova MA
    J Addict Dis; 2018; 37(3-4):135-141. PubMed ID: 31272306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Comparison Between Positive and Negative Symptoms Severity in Prolonged Methamphetamine-induced Psychotic Disorder and Schizophrenia.
    Ahmadkhaniha H; Ayazi N; Alavi K; Najjarzadehgan M; Hadi F
    Basic Clin Neurosci; 2022; 13(3):325-333. PubMed ID: 36457876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Minor neurological and physical anomalies in patients with first-episode psychosis].
    Mhalla A; Boussaïd N; Gassab L; Gaha L; Mechri A
    Encephale; 2013 Jun; 39(3):149-54. PubMed ID: 23095597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cannabis and schizophrenia: demographic and clinical correlates].
    Dervaux A; Laqueille X; Bourdel MC; Leborgne MH; Olié JP; Lôo H; Krebs MO
    Encephale; 2003; 29(1):11-7. PubMed ID: 12640322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of Synthetic Cannabinoid and Cannabis Users Admitted to a Psychiatric Hospital: A Comparative Study.
    Shalit N; Barzilay R; Shoval G; Shlosberg D; Mor N; Zweigenhaft N; Weizman A; Krivoy A
    J Clin Psychiatry; 2016 Aug; 77(8):e989-95. PubMed ID: 27379411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two weeks' quetiapine treatment for schizophrenia, drug-induced psychosis and borderline personality disorder: a naturalistic study with drug plasma levels.
    Mauri MC; Volonteri LS; Fiorentini A; Pirola R; Bareggi SR
    Expert Opin Pharmacother; 2007 Oct; 8(14):2207-13. PubMed ID: 17927477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Study of the Prevalence of Psychiatric Disorders in Patients with Methamphetamine-Induced Psychosis.
    Eslami-Shahrbabaki M; Fekrat A; Mazhari S
    Addict Health; 2015; 7(1-2):37-46. PubMed ID: 26322209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Characteristics and Predictors of Outcome of Schizophrenia-Spectrum Psychosis in Children and Adolescents: A Systematic Review.
    Stentebjerg-Olesen M; Pagsberg AK; Fink-Jensen A; Correll CU; Jeppesen P
    J Child Adolesc Psychopharmacol; 2016 Jun; 26(5):410-27. PubMed ID: 27136403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for an agitated-aggressive syndrome in early-onset psychosis correlated with antisocial personality disorder, forensic history, and substance use disorder.
    Huber CG; Hochstrasser L; Meister K; Schimmelmann BG; Lambert M
    Schizophr Res; 2016 Aug; 175(1-3):198-203. PubMed ID: 27117676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depressive symptoms in acute schizophrenic hospitalized patients.
    Lerner Y; Moscovich D
    J Clin Psychiatry; 1985 Nov; 46(11):483-4. PubMed ID: 4055708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Equipercentile linking of the BPRS and the PANSS.
    Leucht S; Rothe P; Davis JM; Engel RR
    Eur Neuropsychopharmacol; 2013 Aug; 23(8):956-9. PubMed ID: 23433639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disrupted leptin-fatty acid biosynthesis is an early manifestation of metabolic abnormalities in schizophrenia.
    Khan MM
    World J Psychiatry; 2022 Jun; 12(6):827-842. PubMed ID: 35978970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between fear of COVID-19 and depression, anxiety, and psychosis among Lebanese chronic patients with schizophrenia: any moderating effect of spirituality?
    Bitar Z; Haddad C; Obeid S; Hallit S
    Croat Med J; 2022 Oct; 63(5):412-422. PubMed ID: 36325665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A four-dimensional model of chronic schizophrenia based on the factorial structure of the Positive and Negative Syndrome Scale (PANSS). A study of a group of 153 chronic schizophrenic patients and comparison with the factorial structure of the BPRS].
    Loas G; Noisette C; Legrand A; Delahousse J
    Encephale; 1997; 23(1):10-8. PubMed ID: 9172962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale. Reliability, comparability, and predictive validity.
    Bell M; Milstein R; Beam-Goulet J; Lysaker P; Cicchetti D
    J Nerv Ment Dis; 1992 Nov; 180(11):723-8. PubMed ID: 1431824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoid-Induced Psychosis: A Cross-Sectional Gender Study.
    Bachetti MC; Lanzi R; Menculini G; Scopetta F; Tortorella A; Moretti P
    Psychiatr Danub; 2020 Sep; 32(Suppl 1):200-206. PubMed ID: 32890390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of "prodromal" symptoms with severity and type of psychopathology in the active phase of schizophrenia.
    Moukas G; Stathopoulou A; Gourzis P; Beratis IN; Beratis S
    Compr Psychiatry; 2010; 51(1):1-7. PubMed ID: 19932819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative psychopathology of interictal psychosis in epilepsy; interaction between epilepsy-related and psychosis-general effects.
    Ito M; Adachi N; Okazaki M; Hara K; Adachi T; Matsubara R; Sekimoto M; Kato M; Onuma T
    Epilepsy Behav; 2021 Oct; 123():108214. PubMed ID: 34375801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone.
    Robinson DG; Gallego JA; John M; Hanna LA; Zhang JP; Birnbaum ML; Greenberg J; Naraine M; Peters BD; McNamara RK; Malhotra AK; Szeszko PR
    Schizophr Res; 2019 Feb; 204():295-303. PubMed ID: 30241990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.